KR100848197B1 - 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 - Google Patents

신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 Download PDF

Info

Publication number
KR100848197B1
KR100848197B1 KR1020037011205A KR20037011205A KR100848197B1 KR 100848197 B1 KR100848197 B1 KR 100848197B1 KR 1020037011205 A KR1020037011205 A KR 1020037011205A KR 20037011205 A KR20037011205 A KR 20037011205A KR 100848197 B1 KR100848197 B1 KR 100848197B1
Authority
KR
South Korea
Prior art keywords
combination
formula
methyl
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037011205A
Other languages
English (en)
Korean (ko)
Other versions
KR20040025900A (ko
Inventor
엘리자베트 부흐둔거
카를-헨릭 헬딘
아르네 외스트만
크리스티안 피트라스
테렌스 오레일리
존 데이비드 로테르멜
페터 트락슬러
마르쿠스 바르트만
랄프 브란드트
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040025900A publication Critical patent/KR20040025900A/ko
Application granted granted Critical
Publication of KR100848197B1 publication Critical patent/KR100848197B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020037011205A 2001-02-27 2002-02-26 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 Expired - Fee Related KR100848197B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
GB0104840.4 2001-02-27
US33904001P 2001-10-30 2001-10-30
US60/339,040 2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (2)

Publication Number Publication Date
KR20040025900A KR20040025900A (ko) 2004-03-26
KR100848197B1 true KR100848197B1 (ko) 2008-07-24

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037011205A Expired - Fee Related KR100848197B1 (ko) 2001-02-27 2002-02-26 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물

Country Status (22)

Country Link
US (1) US7723339B2 (https=)
EP (1) EP1385522B1 (https=)
JP (1) JP4499359B2 (https=)
KR (1) KR100848197B1 (https=)
CN (1) CN1511036B (https=)
AT (1) ATE434438T1 (https=)
AU (1) AU2002308218B2 (https=)
BR (1) BR0207649A (https=)
CA (1) CA2439268C (https=)
CY (1) CY1109347T1 (https=)
DE (1) DE60232719D1 (https=)
DK (1) DK1385522T3 (https=)
ES (1) ES2326264T3 (https=)
IL (2) IL157466A0 (https=)
MX (1) MXPA03007729A (https=)
NO (1) NO325416B1 (https=)
NZ (1) NZ527764A (https=)
PL (1) PL207197B1 (https=)
PT (1) PT1385522E (https=)
RU (1) RU2313345C2 (https=)
SK (1) SK287489B6 (https=)
WO (1) WO2002067941A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
EP1441736A2 (en) * 2001-10-29 2004-08-04 Novartis AG Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047584A2 (de) * 1999-02-11 2000-08-17 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
MX9800215A (es) * 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047584A2 (de) * 1999-02-11 2000-08-17 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Also Published As

Publication number Publication date
RU2313345C2 (ru) 2007-12-27
BR0207649A (pt) 2004-03-09
CA2439268C (en) 2010-01-19
SK287489B6 (sk) 2010-11-08
NO20033769L (no) 2003-08-25
PT1385522E (pt) 2009-09-04
IL157466A (en) 2012-04-30
DK1385522T3 (da) 2009-10-12
CN1511036A (zh) 2004-07-07
KR20040025900A (ko) 2004-03-26
CN1511036B (zh) 2010-05-05
EP1385522B1 (en) 2009-06-24
ES2326264T3 (es) 2009-10-06
NO325416B1 (no) 2008-04-21
DE60232719D1 (de) 2009-08-06
JP2004527493A (ja) 2004-09-09
SK10712003A3 (sk) 2004-02-03
ATE434438T1 (de) 2009-07-15
AU2002308218B2 (en) 2005-11-10
MXPA03007729A (es) 2003-12-04
US7723339B2 (en) 2010-05-25
PL207197B1 (pl) 2010-11-30
HK1062266A1 (en) 2004-10-29
JP4499359B2 (ja) 2010-07-07
CY1109347T1 (el) 2014-07-02
PL363288A1 (en) 2004-11-15
NZ527764A (en) 2006-01-27
EP1385522A2 (en) 2004-02-04
US20040132754A1 (en) 2004-07-08
RU2003127392A (ru) 2005-03-27
WO2002067941A8 (en) 2003-12-18
IL157466A0 (en) 2004-03-28
WO2002067941A2 (en) 2002-09-06
NO20033769D0 (no) 2003-08-25
WO2002067941A3 (en) 2003-11-20
CA2439268A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
KR100848197B1 (ko) 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물
JP6532878B2 (ja) 組合せ医薬
EP1059100A2 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
JP2004513964A (ja) Ｖｅｇｆ活性低減剤およびｅｇｆ活性低減剤を含む組合せ剤
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
MX2008012903A (es) Uso de inhibidores de c-src en combinacion con un compuesto de pirimidilaminobenzamida para el tratamiento de la leucemia.
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
TW201006823A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
AU2020244921B2 (en) Antitumor composition
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
AU2006255559A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
HK1062266B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
CZ20032277A3 (cs) Kombinace inhibitoru přenosu signálu a derivátu epothilonu k léčení proliferativních onemocnění

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120620

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130718

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130718

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000